Chris Shibutani
Stock Analyst at Goldman Sachs
(0)
# 4589
Out of 5,266 analysts
107
Total ratings
53.85%
Success rate
-14.28%
Average return
Main Sectors:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Alkermes | Maintains: Strong Buy | 30 32 | 35.25 | -9.22% | 5 | Feb 14, 2025 | |
Vaxcyte | Initiates Coverage On: Buy | 135 | 80.86 | 66.96% | 1 | Dec 20, 2024 | |
BioNTech | Upgrades: Buy | 90 137 | 121.64 | 12.63% | 7 | Nov 8, 2024 | |
Syndax Pharmaceutica... | Maintains: Strong Buy | 30 33 | 16.85 | 95.85% | 3 | Nov 7, 2024 | |
United Therapeutics | Maintains: Neutral | 243 302 | 357.63 | -15.56% | 4 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 3 4 | 1.44 | 143.06% | 6 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 50 51 | 33.31 | 53.11% | 3 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 160 155 | 162.21 | -4.44% | 3 | Jul 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 3 4 | 3.48 | 14.94% | 8 | Jul 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 9 8 | n/a | n/a | 5 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 18 20 | 15.54 | 28.7% | 5 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 650 723 | 883.14 | -18.13% | 6 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 29 26 | 22.8 | 14.04% | 1 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 134 153 | 119.91 | 27.6% | 2 | Jan 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Buy | 173 | 202.65 | -14.63% | 4 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | n/a | n/a | n/a | 4 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Sell | 4 2 | 0.81 | 54.32% | 3 | Nov 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 81 69 | 55.52 | 24.28% | 3 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 5 3 | n/a | n/a | 3 | May 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 15 13 | 18.18 | -28.49% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 20 23 | 41.93 | -45.15% | 3 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 117 144 | n/a | n/a | 2 | Jan 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 50 | 1.64 | 2948.78% | 1 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 40 52 | 36.92 | 40.85% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Buy | 47 60 | 26.25 | 128.57% | 2 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 13 18 | 12.98 | 38.67% | 4 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 23 20 | n/a | n/a | 2 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 17 | 2.42 | 602.48% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 90 | n/a | n/a | 1 | May 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | n/a | n/a | n/a | 1 | Jul 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | n/a | n/a | n/a | 1 | Feb 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | n/a | n/a | n/a | 2 | Jan 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | n/a | n/a | n/a | 3 | Jan 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | n/a | n/a | n/a | 1 | Dec 21, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | n/a | n/a | n/a | 2 | May 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | n/a | n/a | n/a | 1 | Mar 24, 2017 |